#1 Clinical Trials Search in Europe

Non-Hodgkin’s lymphoma – Trials in Disease

Go back

Ongoing Clinical Trials for Non-Hodgkin’s Lymphoma

There are currently 16 ongoing clinical trials investigating new treatments for Non-Hodgkin’s lymphoma across multiple countries. These trials are testing various approaches including CAR T-cell therapies, targeted medications, immunotherapies, and combination treatments. Trials are being conducted in several European countries, with some also available in Norway and other locations.

Clinical trial locations

Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy

This trial monitors the long-term safety of patients who have previously received CAR T-cell therapy, a type of treatment that uses genetically modified immune cells to fight disease. The study focuses on patients who received either AUTO1 or AUTO4 therapy along with rituximab.

Inclusion criteria: Participants must have previously received AUTO CAR T-cell therapy in another study and provided informed consent for long-term follow-up. They need to be able to comply with study requirements. The trial is open to both males and females across different age groups, including children, teenagers, and adults.

Exclusion criteria: Patients who have developed a potential malignancy after receiving Autolus CAR T-cell therapy cannot participate.

Main focus: The study monitors participants for serious adverse events, development of new cancers, and other health events of special interest. It also tracks overall survival rates and duration of supportive care needed. Researchers look for remaining genetic material from the therapy in the blood and check for potential causes of new cancers. This follow-up continues for up to 15 years after initial CAR T-cell therapy.

Investigational treatment: The study involves autologous T cells that have been genetically modified using viral vectors. These are collected from the patient and modified in a laboratory to help them better recognize and attack cancer cells.

Study of EO2463, Lenalidomide, and Rituximab for Patients with Indolent Non-Hodgkin’s Lymphoma

This trial investigates EO2463, a vaccine therapy derived from microbial peptides, for patients with indolent forms of the disease including Follicular Lymphoma and Marginal Zone Lymphoma. The study explores EO2463 both as a standalone treatment and in combination with Lenalidomide and Rituximab.

Inclusion criteria: Patients must have Indolent Non-Hodgkin’s Lymphoma (Follicular or Marginal Zone Lymphoma), be 18 years or older, and be HLA-A2 positive. They need measurable disease (lymph node or tumor mass at least 1.5 cm). For certain groups, patients must have relapsed or refractory disease with at least one prior treatment. Others must have newly diagnosed conditions not previously treated. Patients must have a performance status score of 0 to 2, low tumor burden, and use effective birth control methods as required.

Exclusion criteria: The trial excludes patients with other cancer types, those with serious uncontrolled health problems, pregnant or breastfeeding women, those unable to follow procedures, patients with allergies to study medications, recent participation in another trial, uncontrolled infections, certain heart conditions, or severe liver or kidney problems.

Main focus: The trial has two phases. Phase 1 determines the appropriate dose of EO2463 and assesses safety. Phase 2 evaluates how well the treatment works in reducing cancer according to specific criteria. Throughout the study, participants are monitored for side effects and health changes.

Investigational treatments: EO2463 is a new vaccine made from microbial peptides given by injection. Lenalidomide is an immune-modulating medication taken orally that helps the immune system fight cancer. Rituximab targets specific immune system cells and is given by infusion. The study tests these medications individually and in combination.

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

This trial studies lymphoblastic lymphoma treatment in children and adolescents, comparing different medication approaches to improve outcomes. The study involves multiple medications including prednisone, dexamethasone, PEG-asparaginase, methotrexate, and various chemotherapy drugs.

Inclusion criteria: Patients must have newly diagnosed lymphoblastic lymphoma and be under 18 years old. They must be enrolled at a participating center with written informed consent from parents and the patient if over 14 years old. Adequate slides or tissue samples must be provided for reference pathology and genetic testing.

Exclusion criteria: Patients without lymphoblastic lymphoma, those outside the specified age range, those not part of specified clinical trial groups, and those not meeting vulnerability criteria cannot participate.

Main focus: The study evaluates whether using dexamethasone instead of prednisone during initial treatment reduces the risk of cancer returning in the central nervous system. For higher-risk patients, it tests whether more intensive treatment with additional PEG-asparaginase doses and intensified methotrexate courses improves cancer-free survival rates.

Investigational treatments: Prednisone is a steroid used as standard treatment to reduce inflammation. Dexamethasone is the experimental steroid being tested to see if it more effectively reduces relapse risk. PEG Asparaginase breaks down nutrients cancer cells need. Methotrexate is chemotherapy given in high doses to kill cancer cells and prevent multiplication.

Study on Preventing Hypothyroidism in Patients with Medulloblastoma and Pediatric Lymphoma Using Levothyroxine During Radiation Therapy

This trial examines whether Levothyroxine can help reduce the risk of developing hypothyroidism after radiation therapy in patients with medulloblastoma, Hodgkin lymphoma, and non-Hodgkin lymphoma. Hypothyroidism occurs when the thyroid gland doesn’t produce enough hormones.

Inclusion criteria: Patients must have medulloblastoma, Hodgkin lymphoma, or non-Hodgkin lymphoma and be scheduled for radiation therapy that includes the thyroid area. They must not have had previous hypothyroidism and must provide written informed consent. The study is open to males and females across various age groups including children, adolescents, and adults.

Exclusion criteria: Patients not diagnosed with the specified conditions or outside the age range cannot participate. Gender is not an exclusion factor, and vulnerable populations are not excluded.

Main focus: Some patients receive Levothyroxine during radiation treatment while others do not, to determine if it prevents hypothyroidism. Participants are monitored for three years after radiation therapy to check for signs of hypothyroidism and assess long-term thyroid health.

Investigational treatment: Levothyroxine is given as oral tablets at 25 micrograms per dose. It helps replace or supplement thyroid hormones that the gland normally produces, potentially protecting the thyroid during radiation treatment.

Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

This trial explores how market-available targeted anti-cancer drugs can treat advanced solid tumors, non-Hodgkin lymphoma, or multiple myeloma based on specific genetic or protein markers in tumors. The study includes numerous medications such as Rozlytrek, Cabometyx, Lenvima, and many others.

Inclusion criteria: Patients must be adults over 18 with confirmed diagnosis of advanced solid tumor, multiple myeloma, or non-Hodgkin lymphoma that is worsening despite previous treatments or has no other treatment options. Women who can have children and men must use reliable birth control. Patients need ECOG performance status of 0 to 2 and acceptable organ function. Disease must be measurable, and tumor testing must show genetic or protein changes targetable by study drugs. A fresh tumor sample taken within two months is required. Patients must be able to swallow pills if taking oral medications.

Exclusion criteria: Patients without the specified medical conditions, those lacking genomic or protein variants targeted by study drugs, those outside the age range, or part of vulnerable populations cannot participate.

Main focus: Treatment is assigned based on tumor molecular profile. Participants receive various targeted anti-cancer drugs either orally or intravenously. Regular monitoring assesses tumor response and side effects through physical exams, imaging tests, and laboratory work. Primary endpoints include percentage of patients treated based on tumor profile and objective tumor response. Secondary endpoints focus on progression-free survival and overall survival.

Investigational treatments: The study uses targeted anti-cancer drugs specifically chosen based on genetic or protein changes in cancer cells. By focusing on these specific changes, the drugs aim to stop cancer cell growth or kill them, potentially leading to better outcomes.

Study on the Safety and Effects of Inobrodib, Betamethasone Sodium Phosphate, and Dimethyl Fumarate in Patients with Advanced Blood and Bone Marrow Cancers

This trial tests the experimental drug CCS1477 both alone and in combination with other treatments for patients with Acute Myeloid Leukemia, higher-risk Myelodysplastic Syndrome, Multiple Myeloma, and Non-Hodgkin Lymphoma. The study monitors safety and effects on the cancer.

Inclusion criteria: Patients must provide written informed consent and be 18 years or older. Women must use highly effective birth control if sexually active, not be breastfeeding, and have negative pregnancy tests if able to have children, or demonstrate inability to have children through menopause or surgery. Patients need ECOG performance status of 0 or 1 and confirmed diagnosis of specified blood or bone marrow cancers. They must have received standard therapy and not require urgent treatment. Adequate blood and organ function is required. Male participants must use barrier contraception during and after the study.

Exclusion criteria: The trial excludes patients with other cancer types, pregnant or breastfeeding women, those with severe heart problems, uncontrolled infections, recent cancer treatment within 4 weeks, known medication allergies, significant liver or kidney disease, inability to follow procedures, drug or alcohol abuse history, or recent participation in another trial.

Main focus: The study monitors participants receiving CCS1477 as oral capsules, sometimes combined with dexamethasone or pomalidomide. Regular visits check vital signs, conduct laboratory tests, and possibly perform ECGs. The study gathers safety data and assesses medication effectiveness through periodic imaging studies, blood tests, and other evaluations.

Investigational treatment: CCS1477 is a new medication being tested for safety and effectiveness in advanced blood or bone marrow cancers, both alone and in combination with other treatments. It targets specific proteins involved in cancer cell growth and survival.

Study of [90Y]Y-PentixaTher and [68Ga]Ga-PentixaFor in patients with advanced Non-Hodgkin lymphomas: Evaluating radiopeptide-based imaging and therapy

This trial uses two medications for advanced Non-Hodgkin lymphomas: [68Ga]Ga-PentixaFor for detailed imaging of cancer cells and [90Y]Y-PentixaTher for treatment. Both are given as solutions injected into a vein. The treatment targets the CXCR4 protein found on cancer cells.

Inclusion criteria: Patients must be at least 18 years old with confirmed diagnosis of multiple myeloma that has progressed after standard treatments or aggressive B- and T-cell lymphomas that have returned or not responded to at least 2 previous treatments. They need positive 68Ga-Pentixafor PET/CT or PET/MR scan results and stored stem cells available (more than 2 million cells per kilogram). Good physical condition (ECOG score 0-1) and life expectancy over 3 months are required. Adequate organ function is necessary, including acceptable liver function tests, kidney function, and heart and lung function. Written informed consent is required. Women who can become pregnant must not be breastfeeding, must use effective birth control, and have negative pregnancy tests. Men who can father children must use effective birth control for 90 days after treatment.

Exclusion criteria: The trial excludes patients below 18 or above 75 years, pregnant or breastfeeding women, those with known allergies to study medications, active uncontrolled infections, severe kidney or liver dysfunction, recent participation in another trial, inability to provide consent, previous stem cell transplantation, uncontrolled heart conditions, active secondary cancer, mental conditions affecting compliance, bone marrow involvement exceeding 25%, low blood cell counts, or life expectancy less than 3 months.

Main focus: Before treatment, patients undergo special imaging tests using [68Ga]Ga-PentixaFor to confirm their cancer cells have the CXCR4 protein. The study has two phases: Phase 1 tests different doses to find the safest amount, and Phase 2 studies effectiveness at the chosen dose. Treatment combines [90Y]Y-PentixaTher with high-dose chemotherapy followed by stem cell transplantation.

Investigational treatments: Pentixather (labeled with Yttrium-90) is a radioactive drug targeting CXCR4 receptors on cancer cells, delivering radiation directly to them. Melphalan is chemotherapy interfering with cancer cell DNA. Treosulfan is chemotherapy used in high-dose treatments before stem cell transplantation. These are combined with autologous stem cell transplantation.

Study of TdT-3 cell therapy safety in patients aged 1 year and older with relapsed or refractory acute leukemia or lymphoblastic lymphoma

This trial studies TdT-3, a cell therapy using modified immune cells, for treating acute lymphoblastic leukemia or lymphoblastic lymphoma that hasn’t responded to standard treatments or has returned. The therapy involves taking the patient’s T-cells, modifying them in a laboratory, and returning them through bloodstream infusion.

Inclusion criteria: Patients must be at least 1 year old at screening with adequate T-cell recovery (at least 100 CD4+ T cells) from previous therapy. Children under 6 and first 3 patients need an identified stem cell donor. Patients must undergo leukapheresis with at least 150 T cells per microliter. If previously had stem cell transplant, must be at least 100 days since transplant and 30 days since last donor lymphocyte treatment. If previously had CAR T-cell therapy, must be at least 30 days since last treatment. Women who can become pregnant need negative pregnancy tests within 24 hours before key procedures. Life expectancy must be at least 3 months. Patients need suitable blood cells collected through leukapheresis and leukemia or lymphoma that hasn’t responded to standard treatments. Cancer cells must show TdT protein presence and specific genetic marker (HLA-A*02:01). Measurable disease in bone marrow or visible tumors on scans is required. Written informed consent is necessary. Adequate physical function score (Lansky or Karnofsky score ≥50) and adequate kidney, liver, lung, and heart function based on medical tests are required.

Exclusion criteria: The trial excludes patients with other cancer types in the past 2 years (except non-melanoma skin cancer), active central nervous system involvement, uncontrolled infections requiring IV antibiotics, severe heart conditions, severe liver or kidney problems, pregnancy or breastfeeding, known HIV infection, active hepatitis B or C, previous similar cell therapy within 6 months, mental health conditions affecting participation, or any serious medical condition making participation unsafe.

Main focus: The study determines the safest dose and tests how well TdT-3 works. Before receiving cell therapy, patients receive Fludarabine and Cyclophosphamide to prepare their body. Treatment involves blood cell collection through leukapheresis, laboratory processing to create TdT-3 therapy, and giving modified cells back to the patient. Participants undergo regular check-ups and tests monitoring health and treatment progress.

Investigational treatments: TdT-3 uses genetically modified T-cells targeting cells expressing TdT found in certain leukemia and lymphoma types. Fludarabine and Cyclophosphamide are chemotherapy medications used as conditioning treatment before cell therapy, suppressing the immune system to help modified T-cells work better.

Study on the Safety and Effectiveness of Berubicin for Patients with Central Nervous System Lymphomas

This trial tests Berubicin hydrochloride, an anthracycline drug, for treating central nervous system lymphomas affecting the brain and spinal cord. Berubicin is given as intravenous infusion combined with other cancer-fighting drugs.

Inclusion criteria: Patients must provide written informed consent, be at least 18 years old, and have confirmed CNS lymphoma diagnosis by pathologist. They should not have had previous high-dose methotrexate-based chemotherapy. Patients with non-Hodgkin’s lymphoma may have had up to two courses of R-CHOP if they have advanced disease. No investigational therapy within 4 weeks before first study drug dose is allowed. ECOG Performance Status should be between 0 and 3. Patients must be eligible for chemotherapy with adequate bone marrow, heart, kidney, and liver function determined by laboratory tests. Women who can have children must use highly effective birth control starting at least 28 days before treatment and continuing until at least 3.5 months after last dose. Men and their female partners must also use effective birth control during this time.

Exclusion criteria: Patients with central nervous system lymphomas cannot participate.

Main focus: The study evaluates Berubicin’s safety and tolerability when used with other cytostatic agents to determine the best dose for future research. Participants receive either Berubicin or placebo with close health monitoring. The study assesses how well treatment works, how long patients live without disease progression, and how many respond positively. Regular check-ups and tests monitor progress throughout the study.

Investigational treatment: Berubicin is given intravenously and works by interfering with cancer cell DNA, preventing multiplication and leading to their death. It’s classified as an anthracycline chemotherapy drug.

Study on Triptorelin for Fertility Protection in Young Women and Teenagers Undergoing Chemotherapy for Breast Cancer, Leukemia, Lymphomas, and Sarcomas

This trial investigates whether GnRHa (Gonadotropin-Releasing Hormone agonist) can help protect fertility in young women and teenagers with breast cancer, acute leukemia, lymphomas (Hodgkin and non-Hodgkin), and sarcomas during chemotherapy by examining changes in ovarian reserve.

Inclusion criteria: Patients need signed informed consent and must be aged 14-42 at cancer diagnosis. They must be female with breast cancer, acute leukemias, lymphomas (Hodgkin and non-Hodgkin), or sarcomas (osteo, soft tissue, and Ewing) confirmed by histology and assigned for disease-specific chemotherapy. Confirmed menarche is required. ECOG performance status 0-1 is necessary, meaning fully active or able to carry out light work. Adequate bone marrow, kidney, liver, and heart functions and absence of uncontrolled medical or psychiatric disorders are required.

Exclusion criteria: The trial excludes non-female patients, those without specified cancer types, those outside the age range, and vulnerable populations.

Main focus: Participants are randomly assigned to receive either GnRHa (Pamorelin 3.75 mg or 11.25 mg) or placebo as intramuscular injections during chemotherapy. The study follows participants for several years, monitoring ovarian reserve through Anti-Müllerian Hormone (AMH) levels at various points after chemotherapy, along with ultrasounds and blood tests. Follow-up continues at 6 months, 12 months, and annually up to 5 years after treatment.

Investigational treatment: GnRHa works by temporarily putting ovaries to rest, potentially shielding them from chemotherapy’s harmful effects to preserve fertility. The treatment is given through injections during cancer treatment.

Long-Term Safety Study of Venetoclax for Patients with Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Acute Leukemia

This trial studies the long-term safety of venetoclax (ABT-199) for patients who completed a previous venetoclax study. The diseases studied include Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, and Acute Lymphocytic Leukemia.

Inclusion criteria: Patients must have completed a previous venetoclax study with the investigator believing continued treatment is beneficial. They must be willing to follow study procedures. Patients with multiple myeloma receiving venetoclax with a proteasome inhibitor must take preventive antibiotics during treatment and for at least 30 days after stopping. Patients or legally authorized representatives must sign and date a consent form before any study procedures. Patients must agree to follow pregnancy avoidance measures.

Exclusion criteria: Patients with Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, and Acute Lymphocytic Leukemia cannot participate.

Main focus: The study monitors long-term safety while participants continue venetoclax treatment in film-coated tablet form taken orally. Regular monitoring for adverse events occurs throughout the study. Multiple myeloma patients receiving venetoclax with proteasome inhibitors must take specific preventive antibiotics. The study continues until February 27, 2026, gathering comprehensive long-term safety data.

Investigational treatment: Venetoclax is a small molecule BCL-2 inhibitor that targets and blocks specific proteins in cancer cells that help them survive. By blocking this protein, venetoclax helps kill cancer cells and slow disease progression.

Note: The article describes 10 trials in detail. Additional trials are available in Belgium, Denmark, Spain, France, Ireland, Greece, Poland, Croatia, Romania, Hungary, Bulgaria, Finland, Czechia, Norway, Italy, Netherlands, Germany, and Sweden. For information about specific trials in these countries, please refer to the clinical trial locations overview at the beginning of this article.

Summary

The current landscape of clinical trials for Non-Hodgkin’s lymphoma demonstrates a diverse range of innovative approaches being investigated across Europe and beyond. With 16 ongoing trials, research is concentrated in several key areas including advanced cellular therapies, targeted medications, and immunotherapy combinations.

Geographically, France, Spain, Italy, and Poland show particularly strong participation, hosting multiple trials each. Germany and the Netherlands also represent significant research hubs. This broad distribution across European countries provides patients in various locations with potential access to experimental treatments.

The trials encompass different patient populations, from pediatric and adolescent patients to adults, with some studies specifically designed for relapsed or refractory cases where standard treatments have not been successful. Several trials focus on specific subtypes including Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, lymphoblastic lymphoma, and central nervous system lymphomas.

Notable therapeutic approaches include CAR T-cell therapies, which use genetically modified immune cells, and targeted drugs that focus on specific molecular markers in cancer cells. Some trials investigate combination therapies pairing newer agents with established treatments like rituximab or lenalidomide. Long-term safety studies for medications like venetoclax and tazemetostat provide valuable data on extended treatment effects.

The research reflects the ongoing evolution in cancer treatment, moving toward more personalized approaches based on tumor characteristics and genetic markers. Many trials include both dose-finding phases and effectiveness evaluation phases, contributing to the scientific understanding of optimal treatment strategies for this complex group of blood cancers.

Ongoing Clinical Trials on Non-Hodgkin’s lymphoma

  • Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Poland

  • Study of Pirtobrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland

More information about
Non-Hodgkin’s lymphoma:

Connected medications: